Sanjay Kaul, MD

All posts by Sanjay Kaul, MD

July 26th, 2010

Questions for Sanjay Kaul about TIDE and Avandia


CardioExchange’s editor-in-chief Harlan Krumholz discussed the TIDE trial on email with Sanjay Kaul, who was a member of the FDA’s advisory panel last week on Avandia. Here is a lightly edited version of their exchange. Krumholz: What is your response to the FDA announcement that it has placed TIDE on a “partial clinical hold”? Do you […]

March 3rd, 2010

Rosiglitazone: When Evidence Is Inconclusive Even After FDA Approval

We welcome Sanjay Kaul, MD, lead author of a recent American Heart Association/American College of Cardiology science advisory about the cardiovascular risks of thiazolidinedione drugs, to answer our questions about rosiglitazone. We encourage you to ask yours. You and your coauthors call the evidence on the cardiovascular risks of rosiglitazone “inconclusive.” When you prescribe a […]